Drugs / Fuzheng Huayu

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 32 trials
Phase 3 NCT02916641 Jan 2016 → Dec 2018 primary biliary cholangitis Xijing Hospital of Digestive Diseases Unknown No outcome recorded
Phase 3 NCT02916290 Jan 2016 → Dec 2018 primary biliary cholangitis Xijing Hospital of Digestive Diseases Unknown No outcome recorded
Phase 44 trials
Phase 4 NCT02945982 Apr 2018 → Jun 2020 portal hypertension ShuGuang Hospital Unknown No outcome recorded
Phase 4 NCT02945956 Apr 2018 → Jun 2020 portal hypertension ShuGuang Hospital Unknown No outcome recorded
Phase 4 NCT02241590 Sep 2014 → Jun 2019 cirrhosis of liver ShuGuang Hospital Unknown No outcome recorded
Phase 4 NCT02241616 Sep 2014 → Jun 2019 cirrhosis of liver ShuGuang Hospital Unknown No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00854087 Comparator Aug 2010 → Apr 2013 chronic hepatitis C virus infection Tarek Hassanein Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as Fuzheng Huayu ClinicalTrials.gov intervention name — accepted as the source's own label NCT02241616
6

NCT02945956

NCT02916641

NCT02916290

NCT00854087

NCT02241590

NCT02945982

Known as Fuzheng Huayu Tablet “Chinese medicines (CMs), particularly Fuzheng Huayu Tablet (, FZHY), have an antifibrotic effect in patients with CHB.” PMID 32572776 Jun 2020
Known as FZHY “Chinese medicines (CMs), particularly Fuzheng Huayu Tablet (, FZHY), have an antifibrotic effect in patients with CHB.” PMID 32572776 Jun 2020
Modality Traditional medicine (herbal / TCM) “anti-fibrotic herbal product such as FZHY” PMID 32572776 Jun 2020
Route Oral “4 FZHY tablets (1.6 g) three times a day” PMID 32642592 Jun 2020